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OBJECTIVE — Toreviewthecurrentknowledgeaboutnonpharmacologicapproachesinthe
prevention and early treatment of type 2 diabetes.
RESEARCH DESIGN AND METHODS — This study reviewed the research reports
dealing with nonpharmacologic interventions aimed at preventing type 2 diabetes with early
lifestyle interventions.
RESULTS — The results from the randomized controlled trials all show that people with
impaired glucose tolerance who received enhanced lifestyle advice had signiﬁcantly lower (on
average 50% reduced) incidence of type 2 diabetes compared with those allocated to receive
“usualcare.”Individualswhowereabletocorrecttheirlifestylehabitsasrecommendedforusual
healthy life patterns were mostly protected against type 2 diabetes. Thus, compelling evidence
existsthatmostofthecasesoftype2diabetescanbepreventedoratleasttheonsetofthedisease
can be signiﬁcantly delayed.
CONCLUSIONS — Randomized controlled trials have unequivocally demonstrated that
lifestyle management is highly efﬁcient in the prevention and also in the early management of
type2diabetes.Thisevidenceoflifestylemodiﬁcationindiabetespreventionisstrongerthanfor
most other multifactorial diseases.
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t is well known that obesity, unbal-
anced diet, and physical inactivity are
the major risk factors for diabetes. In
people genetically predisposed to the dis-
ease, the probability to develop type 2
diabetes is high once exposed to “un-
healthy” lifestyles. In understanding the
potential for prevention of type 2 diabe-
tes, it is important to understand the
enormity of a preventive lifestyle inter-
vention. The development of type 2 dia-
betes is a slow process that takes a long
time and involves both genetic and envi-
ronmental effects (1). It is commonly
agreed that type 2 diabetes may develop
only in subjects that carry a genetic pre-
disposition to the disease. Based on epi-
demiological observations, about half of
the people or even more in some popula-
tions will develop type 2 diabetes during
their lifetime, and up to 30–35% will
have impaired glucose tolerance (IGT)
(2,3).Therefore,itislikelythatmorethan
half of the people carry genes that predis-
pose the development of type 2 diabetes.
Even though genetic effects are important
for the development of the disease, it is
not possible to modify them to prevent
type 2 diabetes. Until recently, evidence
regarding the prevention of type 2 diabe-
tes based on proper randomized con-
trolled trials has been virtually missing.
Type 2 diabetes is also a very expen-
sivedisease;10–15%ofthetotalhealth
care costs in developed countries are
spent treating type 2 diabetes and, in par-
ticular, its complications (4). To avoid
late complications of type 2 diabetes and
related costs, primary prevention of type
2diabetesitselfanditsearlytreatmentare
therefore necessary. The efﬁcacy of pre-
vention in subjects with IGT has been
tested, and currently there is unequivocal
and strong evidence that we can prevent
ordelaytheprogressionofhyperglycemia
to type 2 diabetes.
Data from certain population groups
show that experiencing rapid westerniza-
tion is accompanied by a rapid increase in
the rates of obesity and type 2 diabetes (5).
Can the situation be reversed by reversing
these lifestyle changes? Yes, this has been
demonstrated among Australian Aborigi-
nals by O’Dea (6). In these studies, hyper-
glycemic subjects reverted to living
naturally, in the traditional hunter-gatherer
way of life. As a result, hyperglycemia was
reversed.
The main risk factors for type 2 dia-
betes are obesity and sedentary lifestyle
(7). A “westernized” dietary pattern with
low ﬁber and high saturated and trans
fats, reﬁned carbohydrates, sweetened
beverages, sodium, and red meat intake
have been shown to be associated with
increased type 2 diabetes risk (8). An-
otherfeatureofmodernlifestyle,sleepde-
privation or irregularity, has also been
shown to increase diabetes risk (9). For-
tunately, there are also protective factors
in modern lifestyle: data are being accu-
mulated on the decreased type 2 diabetes
risk associated with coffee and moderate
alcohol intake, particularly wine con-
sumption (10,11).
It is a well-known fact that antidia-
betic drug treatment in type 2 diabetes
has only a limited effect on glycemic con-
trol, which deteriorates in diabetic pa-
tients despite intensive treatment, as
demonstrated in newly diagnosed type 2
diabetic patients in the U.K. Prospective
Diabetes Study (12). Thus, it is obvious
that interventions to prevent increase in
blood glucose must start much earlier
than when clinical symptoms of diabetes
occur, ideally before glucose levels reach
the values considered as diabetes or clin-
ical symptoms due to the disease. In peo-
ple with IGT, approximately half develop
type 2 diabetes during a 10-year fol-
low-up (13), and in Asian populations,
the rate of progression seems to be even
faster (14,15). It is well known that the
riskofcomplicationsbeginsalreadyinthe
pre-diabetic phase before blood glucose
levels reach diagnostic cut points for type
2 diabetes (16). Thus, waiting until indi-
viduals attain the diagnostic criteria for
type 2 diabetes will result in signiﬁcant
morbidity and mortality from cardiovas-
culardisease(17,18).Thevastmajorityof
costs in type 2 diabetes are due to the
secondary and tertiary care of type 2 dia-
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tions, primarily cardiovascular disease
(CVD) (4). Up to 80% of type 2 diabetic
patients will have CVD. With increasing
number of type 2 diabetic patients world-
wide, the number of patients with CVD
will inevitably also rise. The only logical
way to prevent this projected increase in
healthcarecostsistopreventorpostpone
the onset of type 2 diabetes.
LIFESTYLE TRIALS IN
PEOPLE WITH IGT TO
PREVENT PROGRESSION
TO TYPE 2 DIABETES—I nt h e
early randomized intervention study in
Malmo ¨hus, Sweden (19), lower rates of
type 2 diabetes was found in IGT men
randomized to dietary intervention com-
pared with those who received no ther-
apy. More recently, several trials have
tested the efﬁcacy of lifestyle intervention
in prevention of type 2 diabetes.
The feasibility of diet and exercise in-
tervention in men with IGT was assessed
in another study in Malmo ¨, Sweden (20).
Becausethereferencegroupcomprisedof
men who did not want to join the inter-
vention, the groups were not randomly
assigned. The lifestyle intervention aimed
at reducing the intake of reﬁned sugar,
simple carbohydrates, fat, saturated fat,
energy,andalcoholandanincreaseinthe
intakeofcomplexcarbohydratesandveg-
etables. Physical activity training con-
sistedoftwoweekly60-minsessionswith
various dynamic activities. By the end of
the 5-year study period, 11 and 29% of
the men in the intervention group and
reference group had developed type 2 di-
abetes, respectively. Overall, the progres-
siontodiabetesintheseSwedishmenwas
relativelylow,eveninthereferencegroup
compared with the data from the obser-
vational studies (1). The intervention re-
sulted in signiﬁcant changes in lifestyle
and physiological parameters.
In another study, 577 subjects with
IGT were assigned either to a control, ex-
ercise alone, diet alone, or exercise plus
diet group in Da-Qing, China (14), using
a cluster-randomized trial design. Partic-
ipants were assigned to clinics for dietary
intervention and were encouraged to re-
duce weight if BMI was 25 kg/m
2 (61%
of all participants) aiming at 23 kg/m
2;
otherwisehigh-carbohydrate(55–65%of
energy) and moderate-fat (25–30% of en-
ergy) diet was recommended. The partic-
ipants were encouraged to increase their
levelofleisure-timephysicalactivitybyat
least 1–2 “units” per day in clinics as-
signed to exercise intervention. One unit
would correspond for instance to 30 min
slow walking, 10 min slow running, or 5
min swimming. The cumulative 6-year
incidence of type 2 diabetes was lower in
eachofthethreeinterventiongroups(41–
46%) compared with 68% in the control
group.
The results of the Finnish Diabetes
PreventionStudy(DPS)providedtheﬁrst
convincing evidence from a proper ran-
domized controlled trial that type 2 dia-
betes can be prevented by lifestyle
modiﬁcation (21). A total of 522 individ-
uals with IGT were randomized to either
anintensivelifestyleoracontrolinterven-
tion: during an average of 3.2 years of fol-
low-up, type 2 diabetes incidence was
reduced by 58% in the lifestyle group.
Thelifestyleinterventiongoalswere1)re-
duction in weight of 5%, 2) total fat in-
take 30% of energy, 3) saturated fat
intake 10% of energy, 4) ﬁber intake
15 g/1,000 kcal, and 5) moderate exer-
cise for 30 min/day. During the ﬁrst
year of the study, body weight decreased
on average 4.5 kg in the intervention
group and 1.0 kg in the control group
subjects (P  0.0001). Indicators of cen-
tral adiposity and fasting glucose and in-
sulin, 2-h postchallenge glucose and
insulin, and A1C were all reduced signif-
icantly in the intervention group com-
pared with the control group at 1-year
examination (Fig. 1).
The U.S. Diabetes Prevention Pro-
gram (DPP) (22) recruited 3,234 individ-
ualswithIGT(andfastingplasmaglucose
95 mg/dl) who were randomized to re-
ceive intensive dietary and exercise coun-
seling, metformin, or placebo. The main
aims of the intervention were 7%
weight reduction and 150 min/week
moderate physical activity. The relative
risk reduction after 2.8 years was 58% in
the lifestyle intervention group compared
with the placebo group. The effect of life-
style was higher than the effect of met-
formin, which showed 35% relative risk
reduction. During the ﬁrst year of the in-
tervention, weight reduction was 5.6 kg
(6%), with slight, gradual regain to the
end of the study at year 4 (23).
The Indian Diabetes Prevention Pro-
gram (14) recruited 531 people with IGT
who were randomized into four groups
(control, lifestyle modiﬁcation, met-
formin, and combined lifestyle mod-
Figure 1—Changes in clinical and metabolic characteristics among the intervention and control group participants of the DPS. 2h-P-gluc, 2-h
plasma glucose; DIAST, diastolic blood pressure; F-P-gluc, fasting plasma glucose; S, serum; SYST, systolic blood pressure.
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modiﬁcation included advice on physical
activity (30 min of brisk walking per day)
and reduction in total calories, reﬁned
carbohydrates and fats, avoidance of
sugar, and increase in ﬁber-rich foods.
The intensity of the intervention was
lower than in the DPP and DPS. After me-
dian follow-up of 30 months, the relative
risk reduction in type 2 diabetes inci-
dence was with lifestyle modiﬁcation,
26.4% with metformin, and 28.2% with
lifestyle modiﬁcation and metformin, as
compared with the control group. Thus,
there was no added beneﬁt from combin-
ing the pharmacologic and lifestyle
interventions.
The Japanese trial (24) included 458
IGT men randomized to receive either in-
tensive lifestyle intervention (n  102) or
standard intervention (n  356). The
aims of the intensive intervention were
body weight reduction if BMI was 22
kg/m
2 (otherwise, to maintain present
weight), to consume large amounts of
vegetables while reducing the amount of
otherfoodsby10%,reductionoffat(50
g/day) and alcohol intake (50 g/day),
and physical activity 30–40 min/day.
Thecumulative4-yearincidenceoftype2
diabetes in the intervention group was
67% lower than in the control group.
Body weight decreased by 2.2 and 0.4 kg
in the intervention and control groups,
respectively.
LONG-TERM
EFFECTIVENESS OF
LIFESTYLE PREVENTION OF
TYPE 2 DIABETES IN
PEOPLE WITH IGT— The trials
listed above have demonstrated the ben-
eﬁts of healthy lifestyle on delaying the
deteriorationofglucosetolerancetoman-
ifest type 2 diabetes, at least as long as the
intervention continued. Data on possible
long-term effects of such active lifestyle
counseling are scarce. The 12-year fol-
low-up of the Malmo ¨ study (25) revealed
that mortality among men in the former
IGT intervention group was lower than in
thecontrolgroup(6.5vs.14.0/1,000per-
son-years, P  0.009).
In a median 7-year follow-up of the
DPS, the marked reduction in type 2 dia-
betes incidence was sustained (13). More
importantly, after a median postinterven-
tion follow-up of 3 years, type 2 diabetes
incidence was 4.6 and 7.2 per 100 per-
son-years in the intervention and control
groups, respectively (log-rank test, P 
0.0401),i.e.,a36%additionalriskreduc-
tion.Theabsoluteriskdifferencebetween
groups increased during the postinter-
vention period: intensive lifestyle inter-
vention for a limited time can yield long-
term beneﬁts on type 2 diabetes risk in
individuals with IGT.
The 20-year follow-up of the original
Da Qing cohort showed that a lower type
2 diabetes incidence persisted in the life-
style intervention groups (combined)
compared with control participants. The
risk reduction remained essentially the
same also during the postintervention pe-
riod (26). Li et al. (26) observed no statis-
tically signiﬁcant differences in CVD
events, CVD, or total mortality between
the control group and the combined in-
tervention groups, but CVD mortality
tended to be lower (17%) among indi-
viduals who had received lifestyle
intervention.
CLINICAL TRIAL EVIDENCE
OF THE EFFECT OF LIFESTYLE
FACTORS ON TYPE 2
DIABETES RISK— In most of the
published prevention trials, the main aim
wastoseeifcomprehensivelifestyleinter-
vention reduces type 2 diabetes risk. In
the Chinese prevention study (14), an at-
tempt to determine whether diet or exer-
cise intervention is more effective by
randomizing the participating clinics to
diet only, physical activity only, or diet
plus physical activity intervention re-
vealed no difference in outcome between
the two interventions.
In the DPS, the risk of being diag-
nosed with diabetes was strongly associ-
ated with the number of lifestyle goals
achieved (21). Success in achieving the
intervention goals in the DPS was esti-
mated from the food records and exercise
questionnaires. The success score (from 0
to 5) was calculated as the sum of
achieved lifestyle goals. There was a
strong inverse correlation between the
success score and the incidence of diabe-
tes during the total follow-up. This was
especially apparent when the success in
achievingthegoalswasassessedatyear3,
whichprobablyreﬂectstheimportanceof
sustained lifestyle changes (13). The haz-
ardratioswere1.00,0.87,0.67,0.70,and
0.23, for success scores from 0 to 4–5,
respectively (P for trend 0.001).
The effects of various components of
interventionareinteresting,andtherefore
some post hoc analyses related to this is-
sue were completed. The independent ef-
fects of achieving the success score
components at 3-year examination were
assessed by including each of the ﬁve life-
style goal variables individually in a Cox
model (Table 1). Univariate hazard ratios
fordiabetesincidence(95%CI)were0.45
(0.31–0.64) for weight reduction from
baseline, 0.65 (0.45–0.95) for intake of
fat, 0.59 (0.31–1.13) for intake of satu-
rated fat, 0.69 (0.49–0.96) for intake of
ﬁber, and 0.62 (0.46–0.84) for physical
activity, comparing those who did or did
not achieve the respective goal. When all
the ﬁve success score components were
simultaneously included in the Cox
model, the multivariate-adjusted hazard
ratios for diabetes (95% CI) were 0.43
(0.30–0.61) for weight reduction, 0.80
(0.48–1.34) for intake of fat, 0.55 (0.26–
1.16) for intake of saturated fat, 0.97
(0.63–1.51) for intake of ﬁber, and 0.80
(0.57–1.12)forphysicalactivity.Further-
more, weight change was signiﬁcantly as-
sociated with the achievement of each of
the other four lifestyle goals, and conse-
quently, success score was strongly and
inversely correlated with weight reduc-
tion (27).
Correspondingly, the reduction in
body weight was reported to be the main
determinant of risk reduction in the U.S.
DPP(23).Afteradjustmentforothercom-
ponents of the intervention, there was a
16% reduction in diabetes risk per 1 kg
weight lost during the ﬁrst year of the in-
tervention.Furthermore,lowerpercentof
calories from fat and increased physical
activity predicted weight loss, and in-
creasedphysicalactivitywasimportantto
help sustain weight loss. Achieving the
physical activity goal of 150 min/week re-
duced diabetes risk, especially among
those participants who did not achieve
theweightreductiongoalof7%,withrisk
reduction of 44% compared with those
who achieved neither the weight reduc-
tion nor the physical activity goal.
These ﬁndings suggest that dietary
composition and physical activity are im-
portant in diabetes prevention, but their
effect on diabetes risk is primarily medi-
ated through resulting weight reduction.
Nevertheless,becauseofmulticolinearity,
the interpretation of the results should be
done cautiously. It should also be noted
that in the Indian Diabetes Prevention
Program (15) and Chinese prevention
study (14), the participants were rela-
tively lean, and there was no large change
in body weight, but despite that, a re-
markable reduction in diabetes risk was
apparent. Thus, in these studies, compo-
nents of the intervention other than
Tuomilehto
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beneﬁcial effects on diabetes risk.
COMMENT— With compelling evi-
dencethattype2diabetescanbeprevented
ordelayed,strategiestoimplementthepri-
mary prevention of type 2 diabetes both
in high-risk subjects as well as at the pop-
ulation level are urgently needed. While
type 2 diabetes prevention trials rigor-
ously deﬁned populations by explicitly
characterizingtheirglycemicstatus,these
studies did not include all groups at risk
for developing type 2 diabetes. Methods
that can also deﬁne other groups at high
risk for developing type 2 diabetes have
been recently developed and are increas-
ingly used in several countries (28). The
recent analysis of the DPS has also shown
that such people will signiﬁcantly beneﬁt
from lifestyle interventions (27).
Aprospectivestudybasedonthedata
from the U.K. estimated the association
between the achievement of the ﬁve life-
style goals used in the DPS and the type 2
diabetesriskdevelopingdiabetesduringa
4.6-year follow-up (29). The incidence of
type 2 diabetes was inversely related to
the number of goals achieved (P 
0.001). None of the participants who met
all ﬁve of the goals (0.8% of the total pop-
ulation) developed diabetes, whereas the
risk of diabetes was highest in those who
did not meet any of these goals. If the
entire population were able to meet one
more goal, the total incidence of diabetes
is predicted to decrease by 20%. This
ﬁnding suggests that health promotion
interventions that result in an increase in
healthy lifestyle in the general population
might signiﬁcantly reduce the growing
burden of type 2 diabetes.
Groupsthatwillbethetargetsforpre-
vention efforts can be identiﬁed through
several reasonably effective strategies.
However,thereisnouniversalwell-tested
method that will identify all at high risk
for developing type 2 diabetes, and there
may be some variation in the optimal
strategiesfordifferentpopulationsandre-
gions around the world. It is also impor-
tant to realize that the identiﬁcation of
people having a high risk of type 2 diabe-
tes or asymptomatic type 2 diabetes is not
identical with the diagnosis of type 2 dia-
betes. In practice, we can identify people
at high risk with simple and cost-efﬁcient
tools. The main question, however, is
how to implement an efﬁcient preventive
strategy in individuals identiﬁed to be at
high risk, i.e., how to translate the results
of the recent successful type 2 diabetes
prevention trials to a real-life setting (30).
Much attention has been put on the bio-
chemical methods for the assessment of
glycemia in the early diagnosis of type 2
diabetes,butmuchlessonthecoverageof
the detection of asymptomatic type 2 di-
abetes. The evidence is compelling that
without applying an oral glucose toler-
ancetestoranassessmentofpostprandial
glucose, a large proportion of early cases
of type 2 diabetes will remain unrecog-
nized (31).
The International Diabetes Federa-
tion Consensus Group recently prepared
a document on the prevention of type 2
diabetes (32). This shows that the inter-
national diabetes community is now
ready to accept the principle that the pri-
mary prevention of type 2 diabetes must
be considered as an essential part of pub-
lic health policy for diabetes.
The American Diabetes Association
consensus development conference in
2006 outlined principles regarding im-
paired fasting glucose (IFG) and IGT and
interventions to be applied among such
individuals (26). The American Diabetes
Association consensus group also recom-
mended lifestyle intervention initially for
people with IFG or IGT (weight control
and physical activity) but does not men-
tion diet at all. If both IFG and IGT are
present as well as additional risk factors
(and most of such people have additional
risk factors), then a combination of life-
style intervention and metformin is rec-
ommended. However, the evidence is not
theretoshowthatthecombinationoflife-
style and metformin is effective; on the
contrary, the results from the Indian Dia-
betes Prevention Program suggest that
there is no additional beneﬁt from met-
formin over and above lifestyle interven-
tion (15). It is not clear how much
antidiabetic drugs can help in preventing
progression from IFG or IGT to overt di-
abetes and what is their overall costs and
risk/beneﬁt ratio in the long term. It is
evident that long-term effects of lifestyle
interventions are highly beneﬁcial and
that long-term costs are very low (13,26).
Colaqiurietal.(33)intheiranalysisstress
that the real answer to reductions in inci-
dence and prevalence of diabetes is in so-
cial policy, not in medical care. This is
likely to be the reality.
Table1—Multivariatelogisticregressionmodeltopredictdiabetesduringa10-yearfollow-up
Odds ratio (95%
CI)
Coefﬁcient
 Score*
Intercept — 5.658
Age (years)
45 1 0 0
45–54 1.92 (1.13–3.25) 0.650 2
55–64 2.56 (1.53–4.28) 0.940 3
BMI (kg/m
2)
25 1 0 0
25–30 1.02 (0.48–2.15) 0.015 1
30 2.55 (1.10–5.92) 0.938 3
Waist circumference (cm)
Men 94, women 80 1 0 0
Men 94 to 102, women 80 to 88 2.78 (1.43–5.40) 1.021 3
Men 102, women 88 4.16 (2.00–8.63) 1.424 4
Blood pressure medication
No 1 0 0
Yes 2.04 (1.45–2.88) 0.714 2
History of high blood glucose
No 1 0 0
Yes 9.61 (6.31–14.63) 2.263 5
Physical activity
4 h per week 1 0 0
4 h per week 1.31 (0.88–1.95) 0.268 2
Consumption of vegetables, fruits, or berries
Every day 1 0 0
Less often than once a day 1.18 (0.85–1.64) 0.165 1
Area under the receiver-operating
characteristic curve 0.860 0.852
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